![]() | |
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C28H44N4O8 |
Molar mass | 564.680 g·mol−1 |
3D model (JSmol) | |
| |
|
Mizagliflozin is an SGLT1 inhibitor developed as a potential treatment for chronic constipation. [1] [2] It progressed as far as Phase II trials in humans but was not approved for medical use, however it has since been investigated for other applications. [3] [4]